Below are brief introductions to meningococcal disease and the meningococcal vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.
Meningococcal disease is a bacterial infection caused by the bacteria Neisseria meningitidis (N. meningitidis).1 There are thirteen identified types (serogroups) of N. meningitidis or meningococci,2 with six causing epidemics resulting in invasive meningococcal disease. Meningitis is the most common form of invasive meningococcal disease, accounting for about 75 percent of all cases.
Symptoms of meningitis usually appear between three and seven days after exposure to the meningococcal bacteria. At first, symptoms may appear mild and similar to cold or flu symptoms, such as headache, fever, aches, and pains. As the illness progresses, additional symptoms may arise, including skin rash, severe headache, stiff neck, nausea, vomiting, inability to look at bright lights, mental confusion and irritability, extreme fatigue/sleepiness, convulsions, and unconsciousness. In babies, symptoms may include a high-pitched moaning cry, difficulty or refusal to feed, and bulging of the fontanel (the soft area on the top of the head).34
There are currently seven FDA licensed meningococcal vaccines in the U.S. However, two vaccines, Menactra and Menomune, are no longer produced. 567 In total, these vaccines target five of the 13 meningococcal serotypes. Menveo, MenQuadfi, and PENBRAYA are conjugate vaccines that target serogroups A, C, Y and W-135.8 BEXSERO and TRUMENBA are recombinant vaccines that target serogroup B.
The CDC recommends that children 11 to 12 years of age receive the first dose of ACWY meningococcal vaccine conjugate, and a booster dose at age 16. For individuals at age 16 or older, vaccines for all currently available serogroups (A, C, W, Y and B) are recommended by the CDC. The CDC also recommends that high risk children between 2 months and 10 years and high-risk adults be vaccinated with meningococcal conjugate vaccine.